Frost & Sullivan ranks RapidAI's enterprise platform ahead of 96% in the industry

Get report
Skip to content

Frost & Sullivan ranks RapidAI's enterprise platform ahead of 96% in the industry

Get report
  • There are no suggestions because the search field is empty.
Request a Demo
Request a Demo

Core Capabilities

Featured

Radar metrics
BLOG The market has changed: Frost & Sullivan's 2026 Radar shows who's leading it RapidAI Chief Business Officer David Stoffel, MD, MBA, breaks down what this recognition signals — and what it means for health systems planning their AI strategy for the years ahead LEARN MORE
Platform overview
Request a Demo

RADIOLOGY SUPPORT

Neurovascular

Cardiac + vascular

LIFE SCIENCES

Featured

Cognitive Burden index RapidAI 2025
BLOG Radiology’s real challenge Read about the reality of cognitive burden LEARN MORE
Request a Demo

BUILT TO SUPPORT THE FULL SYSTEM

FEATURED

Resource_1600x900_C-Suite-Exec Insights_white paper
WHITE PAPER Empowering healthcare leaders with a deep clinical AI enterprise platform Learn how AI can address real-world challenges for administrators LEARN MORE
Overview
Request a Demo

Core Capabilities

Featured

Radiology Rewired podcast
PODCAST Season 1 available now Exploring how AI is transforming Radiology—one conversation at a time with clinicians and innovators LEARN MORE
Overview
Request a Demo

TRAINING & LEARNING

HELP & ASSISTANCE

Overview
Request a Demo

LEARN MORE ABOUT RAPIDAI

WORK WITH US

FEATURED

video thumbnail for dr Gregory Albers
VIDEO The story behind RapidAI Hear our founder, Greg Albers, MD, tell the history of how the company came to be Watch now
Company overview
Request a Demo
Press Release

iSchemaView Receives FDA Clearance for Rapid CTA

Leader in Advanced Cerebrovascular Imaging First to Meet the Needs of Large and Small Centers and Hospitals with New CTA Support and 3D Imaging Added to Complete Suite of Rapid Offerings

Share to

Leader in Advanced Cerebrovascular Imaging First to Meet the Needs of Large and Small Centers and Hospitals with New CTA Support and 3D Imaging Added to Complete Suite of Rapid Offerings

Redwood City, Calif. – May 1, 2018 – iSchemaView, the leader in cerebrovascular imaging analysis, today announced it has received final clearance from the U.S. Food and Drug Administration (FDA) for RAPID CTA, the company’s 3D imaging solution for Computed Tomography Angiography. RAPID CTA is the newest addition to iSchemaView’s industry leading neuroimaging platform — including RAPID CTP and RAPID MRI — which is designed to provide physicians with fast, fully-automated, elegant and easy-to-interpret imaging that facilitates clinical decision making around cerebrovascular disease, such as stroke. In simplest terms, CTA provides visualization of blood vessels in the brain. Using an injectable contrast agent, high-tech X-ray imaging and sophisticated computer analysis, a CT angiogram provides physicians with detailed and accurate images of the vasculature. However, interpreting standard CTA output is a cumbersome timeconsuming process. RAPID CTA automatically provides clear, easy to interpret CTA maps which include a colored overlay to identify brain regions with reduced blood vessel density. The severity of reduction can be readily visualized by a simple, four-color-coded scale. Additionally, a 3D reconstruction of the vasculature allows physicians to rotate the image for optimal viewing of the vessels from multiple angles. All of this in a few minutes. RAPID CTA is a phenomenal tool for all doctors involved in neurovascular emergencies – from the ER doctor making decisions about patient transfer to the neurointerventionalist getting ready for an incoming thrombectomy procedure. “Our goal is to provide healthcare professionals around the world with the most comprehensive and intuitive suite of imaging solutions possible,” said Don Listwin, CEO of iSchemaView. “With new FDA clearance and the release of RAPID CTA, we are making good on that goal. We ensure physicians can take advantage of RAPID’s power whether they choose plain CT, CT Angiography, CT Perfusion or MR diffusion and perfusion. It’s all about offering them the right imaging solution choice, for the right patient at the right time.” In an effort to save valuable diagnosis and treatment time, RAPID CTA also offers remote viewing for physicians in the hospital, at home or on the road. Image maps are immediately available to doctors for review on any desktop or mobile device. RAPID CTA maps provide an intuitive and easy to interpret view of the brain vessels, helping physicians with: Clinical decision making Patient triage Collaboration between community hospitals and specialists Appropriate patient transfers to specialty centers “Many eligible stroke patients with large vessel occlusions must be quickly transferred to a comprehensive stroke center. The new automated RAPID CTA tool makes it easy for community hospitals to quickly identify potential candidates for treatment and for experts at the comprehensive centers to verify that the patient is appropriate for transfer,” said Greg Albers, Professor of Neurology at Stanford University, Director of the Stanford Stroke Center and cofounder of iSchemaView. “With the addition of CTA to RAPID’s FDA indications, hospitals and clinics of all sizes and locations can now use the platform to immediately review images from wherever they are. That’s powerful.”

Contact PR

Jessica Stebing

Jessica Stebing

Group Manager, Marketing Communications

stebing@rapidai.com